SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Ionis Pharmaceuticals (IONS)
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
4676 121 0 IONS
Emcee:  Keith Fauci Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3651Yeah, they said as much in the PR. 2 years cash. The ApoB program seems to shotuck-3/1/2005
3650i'm listening right now. lipid lowering drug and diabetes are the key focusbob zagorin-3/1/2005
3649[HCV RNA replication inhibitors; Merck] >>J Med Chem. 2005 Feb 24;48(4):1tuck-3/1/2005
3648Isis Pharmaceuticals Reports Financial Results and Highlights for 2004 Tuesday Mbob zagorin-3/1/2005
3647Alnylam Data Presented on RNAi Therapeutics for Age-Related Macular Degenerationbob zagorin-2/25/2005
3646Pfizer Inc. (PFE) To Acquire Idun Pharmaceuticals, Inc. NEW YORK and SAN DIEGO,bob zagorin-2/24/2005
3645interesting short interview with needham's mark monane on isis and bio in gebob zagorin-2/24/2005
3644Webcast Alert: Isis Pharmaceuticals Announces 2004 Fourth Quarter Financial Resubob zagorin-2/22/2005
3643<-- Chemistry IP Patent. Alnylam is also pleased to report the issuance of anbob zagorin-2/15/2005
3642Alnylam Pharmaceuticals Reports 2004 Financial Results; Solid Financial Positionbob zagorin-2/15/2005
3641Isis Pharmaceuticals Licenses Antisense Anti-Cancer Drug to Sarissa Monday Februbob zagorin-2/14/2005
3640stand corrected. i always get dizzy looking at those filings. seems like they cobob zagorin-2/8/2005
3639Keep reading, looks like they own around 9%.Joe Wesley-2/8/2005
3638new filing. citygroup owns 5.9% xml.10kwizard.combob zagorin-2/8/2005
3637New Gene Principle Changes the Rules Finding could lead to new treatments for mabob zagorin-1/14/2005
3636Isis Pharmaceuticals Provides Guidance On New Corporate Structure and Research abob zagorin-1/10/2005
3635Getting a CEO would be a logical step...Dr. Voodoo-1/4/2005
3634i wonder if they will spin off IBIS when TIGER is ready to go....bob zagorin-1/4/2005
3633Isis Pharmaceuticals Appoints Michael Treble as Chief Executive Officer of Its Ibob zagorin-1/4/2005
3632isis: brief mention as buy candidate in following... Bearish sentiment breeds obob zagorin-1/3/2005
3631Researchers ID Crohn's mutant gene By Marie Szaniszlo Wednesday, December 29bob zagorin-12/29/2004
3630Eyetech Pharmaceuticals (EYET) To Charge $995 For Macugen (pegaptanib sodium injbob zagorin-12/23/2004
3629Bob, The DRC folks are the same ones that bought royalties from Ligand. Maybe tuck-12/21/2004
3628i have to make a comment about the macugen royalties. when i first saw the macugbob zagorin-12/21/2004
3627Isis Pharmaceuticals to Receive $24 Million for a Portion of Its Macugen(R) Royabob zagorin-12/21/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News